PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS: Financial statements 2017
CVR: 33242840
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS (CVR 33242840) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 25,838,522 and a net result of DKK 1,016,623 compared with DKK 1,162,789 the year before. That is an increase of 9.6% compared with the year before. Equity in the 2017 report amounted to DKK 3,483,928. The solvency ratio was 45.5%. The company had 32 employees in the financial year.
- Gross Profit
- DKK 25,838,522
- Profit/Loss
- DKK 1,016,623
- Equity
- DKK 3,483,928
- Total Assets
- DKK 7,655,260
- Employees
- 32
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 25.8M | 1M | 3.5M | 32 |
| 2016 | - | 23.6M | 1.2M | 2.5M | - |
| 2015 | - | 9.6M | 459K | 1.3M | - |
| 2014 | - | 4.8M | 299K | 845K | - |
| 2013 | - | 3.8M | 238K | 546K | - |
Official annual report
Keep an eye on PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS has published its annual report for 2016. Gross profit came to DKK 23,570,140, and the net result was DKK 1,162,789.
About PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS
PHARMACEUTICAL RESEARCH ASSOCIATES DENMARK ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Thomas Noel O´Leary. The board consists of Thomas Noel O´Leary (chair), John Sheahan and Simon Peter Hollywood. The company is owned by ICON CLINICAL (UK) LIMITED. The company has 49 employees (2026). In 2025, the company reported a gross profit of DKK 61,634,124 and a net result of DKK 3,053,580 compared with DKK 3,554,282 the year before. Equity in the 2025 report amounted to DKK 23,945,884.